JP7281406B2 - ポネシモドを含有する医薬的組み合わせ - Google Patents

ポネシモドを含有する医薬的組み合わせ Download PDF

Info

Publication number
JP7281406B2
JP7281406B2 JP2019549459A JP2019549459A JP7281406B2 JP 7281406 B2 JP7281406 B2 JP 7281406B2 JP 2019549459 A JP2019549459 A JP 2019549459A JP 2019549459 A JP2019549459 A JP 2019549459A JP 7281406 B2 JP7281406 B2 JP 7281406B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
ponesimod
treatment
teriflunomide
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019549459A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510045A (ja
JP2020510045A5 (enExample
Inventor
クローゼル マルティーヌ
プゾル レティシア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of JP2020510045A publication Critical patent/JP2020510045A/ja
Publication of JP2020510045A5 publication Critical patent/JP2020510045A5/ja
Priority to JP2022204487A priority Critical patent/JP2023030091A/ja
Application granted granted Critical
Publication of JP7281406B2 publication Critical patent/JP7281406B2/ja
Priority to JP2024067486A priority patent/JP2024096962A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
JP2019549459A 2017-03-14 2018-03-13 ポネシモドを含有する医薬的組み合わせ Active JP7281406B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022204487A JP2023030091A (ja) 2017-03-14 2022-12-21 ポネシモドを含有する医薬的組み合わせ
JP2024067486A JP2024096962A (ja) 2017-03-14 2024-04-18 ポネシモドを含有する医薬的組み合わせ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2017055994 2017-03-14
EPPCT/EP2017/055994 2017-03-14
PCT/EP2018/056185 WO2018167030A1 (en) 2017-03-14 2018-03-13 Pharmaceutical combination comprising ponesimod

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022204487A Division JP2023030091A (ja) 2017-03-14 2022-12-21 ポネシモドを含有する医薬的組み合わせ

Publications (3)

Publication Number Publication Date
JP2020510045A JP2020510045A (ja) 2020-04-02
JP2020510045A5 JP2020510045A5 (enExample) 2021-04-22
JP7281406B2 true JP7281406B2 (ja) 2023-05-25

Family

ID=61655772

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019549459A Active JP7281406B2 (ja) 2017-03-14 2018-03-13 ポネシモドを含有する医薬的組み合わせ
JP2022204487A Pending JP2023030091A (ja) 2017-03-14 2022-12-21 ポネシモドを含有する医薬的組み合わせ
JP2024067486A Pending JP2024096962A (ja) 2017-03-14 2024-04-18 ポネシモドを含有する医薬的組み合わせ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022204487A Pending JP2023030091A (ja) 2017-03-14 2022-12-21 ポネシモドを含有する医薬的組み合わせ
JP2024067486A Pending JP2024096962A (ja) 2017-03-14 2024-04-18 ポネシモドを含有する医薬的組み合わせ

Country Status (24)

Country Link
US (2) US11723896B2 (enExample)
EP (1) EP3595657A1 (enExample)
JP (3) JP7281406B2 (enExample)
KR (1) KR102574562B1 (enExample)
CN (1) CN110381942B (enExample)
AU (2) AU2018233109B2 (enExample)
BR (1) BR112019018894A2 (enExample)
CA (1) CA3056301C (enExample)
CL (1) CL2019002525A1 (enExample)
CO (1) CO2019008510A2 (enExample)
CR (1) CR20190464A (enExample)
DO (1) DOP2019000257A (enExample)
EA (1) EA201992117A1 (enExample)
EC (1) ECSP19073317A (enExample)
IL (1) IL269239B2 (enExample)
JO (1) JOP20190207A1 (enExample)
MA (1) MA49822A (enExample)
MX (1) MX390941B (enExample)
NI (1) NI201900092A (enExample)
PE (1) PE20191489A1 (enExample)
PH (1) PH12019502110A1 (enExample)
SG (1) SG11201907308UA (enExample)
UA (1) UA125756C2 (enExample)
WO (1) WO2018167030A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190207A1 (ar) * 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
US11014897B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof
US11186556B1 (en) 2018-10-16 2021-11-30 Celgene Corporation Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
US11014940B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Thiazolidinone and oxazolidinone compounds and formulations
US11013723B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms of a thiazolidinone compound, compositions and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007511563A (ja) 2003-11-21 2007-05-10 アクテリオン　ファマシューティカルズ　リミテッド 新規チアゾリジン−４−オン誘導体
JP2008517059A (ja) 2004-10-19 2008-05-22 アベンティス・ファーマスーティカルズ・インコーポレイテツド 炎症性腸疾患を治療するための（ｚ）−２−シアノ−３−ヒドロキシ−ブタ−２−エン酸−（４’−トリフルオロメチルフェニル）−アミドの使用
JP2011514379A (ja) 2008-03-17 2011-05-06 アクテリオン ファーマシューティカルズ リミテッド 選択的ｓ１ｐ１レセプターアゴニストの投与法
WO2016091996A1 (en) 2014-12-11 2016-06-16 Actelion Pharmaceuticals Ltd Dosing regimen for a selective s1p1 receptor agonist

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL178596C (nl) 1975-06-05 1986-04-16 Hoechst Ag Werkwijze voor het bereiden van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor het bereiden van daarin als geneeskrachtige verbindingen te gebruiken 5-methylisoxazool-4-carbonzuuraniliden.
DE2854439A1 (de) 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
US5268382A (en) 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
DE3534440A1 (de) 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
YU61602A (sh) 2000-02-15 2006-01-16 Teva Pharmaceutical Industries Ltd. Postupak za dobijanje leflunomida
WO2002080897A1 (en) 2001-04-05 2002-10-17 Aventis Pharmaceuticals Inc. Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US6894184B2 (en) 2003-03-18 2005-05-17 Aventis Pharma Deutschland Gmbh Process for preparing 2-cyano-3-hydroxy-N-(phenyl)but-2-enamides
USRE43833E1 (en) 2003-11-21 2012-11-27 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
DE102006017896A1 (de) 2006-04-13 2007-10-25 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Leflunomid enthaltende pharmazeutische Zusammensetzungen
US8912340B2 (en) 2006-11-23 2014-12-16 Actelion Pharmaceuticals Ltd. Process for the preparation of 2-imino-thiazolidin-4-one derivatives
ES2410793T3 (es) 2006-11-23 2013-07-03 Actelion Pharmaceuticals Ltd. Nuevo procedimiento para la preparación de derivados de 2-imino-tiazolidin-4-ona
GB0819182D0 (en) 2008-10-20 2008-11-26 Actelion Pharmaceuticals Ltd Crystalline forms
AU2010297357B2 (en) 2009-09-18 2013-11-07 Sanofi-Aventis Deutschland Gmbh (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
WO2012015758A2 (en) 2010-07-30 2012-02-02 Saint Louis University Methods of treating pain
AR082436A1 (es) 2010-08-02 2012-12-05 Sanofi Aventis Us Llc Uso de teriflunomida para tratar la esclerosis multiple
EP2692343A1 (en) 2012-08-03 2014-02-05 Forward Pharma A/S Combination therapy for treatment of multiple sclerosis
EP2885266B1 (en) 2012-08-17 2020-03-18 Actelion Pharmaceuticals Ltd Process for the preparation of (2z,5z)-5-(3-chloro-4-((r)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one and intermediate used in said process
WO2016079687A1 (en) 2014-11-18 2016-05-26 Lupin Limited Oral pharmaceutical composition of teriflunomide
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
US20180185308A1 (en) 2015-06-18 2018-07-05 Matinas Biopharma Nanotechnologies, Inc. Compositions and methods for treating inflammatory disease or conditions
JOP20190207A1 (ar) * 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007511563A (ja) 2003-11-21 2007-05-10 アクテリオン　ファマシューティカルズ　リミテッド 新規チアゾリジン−４−オン誘導体
JP2008517059A (ja) 2004-10-19 2008-05-22 アベンティス・ファーマスーティカルズ・インコーポレイテツド 炎症性腸疾患を治療するための（ｚ）−２−シアノ−３−ヒドロキシ−ブタ−２−エン酸−（４’−トリフルオロメチルフェニル）−アミドの使用
JP2011514379A (ja) 2008-03-17 2011-05-06 アクテリオン ファーマシューティカルズ リミテッド 選択的ｓ１ｐ１レセプターアゴニストの投与法
WO2016091996A1 (en) 2014-12-11 2016-06-16 Actelion Pharmaceuticals Ltd Dosing regimen for a selective s1p1 receptor agonist

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ther Adv Chronic Dis，2016年，7(1)，18-33

Also Published As

Publication number Publication date
SG11201907308UA (en) 2019-09-27
PH12019502110A1 (en) 2020-03-16
UA125756C2 (uk) 2022-06-01
CR20190464A (es) 2019-11-26
CN110381942B (zh) 2022-12-27
ECSP19073317A (es) 2019-11-30
JP2024096962A (ja) 2024-07-17
CA3056301A1 (en) 2018-09-20
AU2018233109A1 (en) 2019-08-22
EA201992117A1 (ru) 2020-02-17
NI201900092A (es) 2020-03-11
JOP20190207A1 (ar) 2019-09-10
KR20190122716A (ko) 2019-10-30
WO2018167030A1 (en) 2018-09-20
IL269239B1 (en) 2023-03-01
JP2020510045A (ja) 2020-04-02
US11723896B2 (en) 2023-08-15
AU2023274118A1 (en) 2023-12-21
AU2018233109B2 (en) 2023-09-28
MX390941B (es) 2025-03-21
MX2019010874A (es) 2019-12-11
DOP2019000257A (es) 2020-09-15
CO2019008510A2 (es) 2019-10-21
MA49822A (fr) 2020-06-17
CA3056301C (en) 2024-10-01
CL2019002525A1 (es) 2020-02-07
BR112019018894A2 (pt) 2020-04-14
IL269239B2 (en) 2023-07-01
EP3595657A1 (en) 2020-01-22
PE20191489A1 (es) 2019-10-21
US20240139161A1 (en) 2024-05-02
KR102574562B1 (ko) 2023-09-04
JP2023030091A (ja) 2023-03-07
IL269239A (en) 2019-11-28
AU2023274118B2 (en) 2024-12-12
CN110381942A (zh) 2019-10-25
US20200069655A1 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
JP7033642B2 (ja) 選択的ｓ１ｐ１レセプターアゴニストを含む薬学的合剤
JP2023030091A (ja) ポネシモドを含有する医薬的組み合わせ
US20250375426A1 (en) Pharmaceutical combination comprising a selective s1p1 receptor agonist
EA041630B1 (ru) Фармацевтическая комбинация, содержащая понесимод

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210310

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220111

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221221

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221221

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230104

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230418

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230502

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230515

R150 Certificate of patent or registration of utility model

Ref document number: 7281406

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350